Banks - Regional
Compare Stocks
2 / 10Stock Comparison
BRBS vs CARE
Revenue, margins, valuation, and 5-year total return — side by side.
Banks - Regional
BRBS vs CARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Banks - Regional | Banks - Regional |
| Market Cap | $314M | $580M |
| Revenue (TTM) | $151M | $255M |
| Net Income (TTM) | $11M | $31M |
| Gross Margin | 63.5% | 61.7% |
| Operating Margin | 9.1% | 15.7% |
| Forward P/E | 31.2x | 4.8x |
| Total Debt | $179M | $179M |
| Cash & Equiv. | $116M | $105M |
BRBS vs CARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Blue Ridge Bankshar… (BRBS) | 100 | 35.2 | -64.8% |
| Carter Bankshares, … (CARE) | 100 | 370.7 | +270.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BRBS vs CARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
BRBS is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 0.54, yield 6.2%
- Lower volatility, beta 0.54, Low D/E 55.4%
- Beta 0.54, yield 6.2%
CARE carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 6.2%, EPS growth 32.1%
- 111.1% 10Y total return vs BRBS's -13.4%
- 6.2% NII/revenue growth vs BRBS's -13.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 6.2% NII/revenue growth vs BRBS's -13.4% | |
| Value | Lower P/E (4.8x vs 31.2x) | |
| Quality / Margins | Efficiency ratio 0.5% vs BRBS's 0.5% (lower = leaner) | |
| Stability / Safety | Beta 0.54 vs CARE's 0.56 | |
| Dividends | 6.2% yield; the other pay no meaningful dividend | |
| Momentum (1Y) | +68.4% vs BRBS's +23.3% | |
| Efficiency (ROA) | Efficiency ratio 0.5% vs BRBS's 0.5% |
BRBS vs CARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
BRBS vs CARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
CARE leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
CARE is the larger business by revenue, generating $255M annually — 1.7x BRBS's $151M. CARE is the more profitable business, keeping 12.3% of every revenue dollar as net income compared to BRBS's 7.1%.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $151M | $255M |
| EBITDAEarnings before interest/tax | $15M | $46M |
| Net IncomeAfter-tax profit | $11M | $31M |
| Free Cash FlowCash after capex | $9M | $30M |
| Gross MarginGross profit ÷ Revenue | +63.5% | +61.7% |
| Operating MarginEBIT ÷ Revenue | +9.1% | +15.7% |
| Net MarginNet income ÷ Revenue | +7.1% | +12.3% |
| FCF MarginFCF ÷ Revenue | +2.5% | +12.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +2.6% | +8.3% |
Valuation Metrics
CARE leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
At 18.7x trailing earnings, CARE trades at a 40% valuation discount to BRBS's 31.2x P/E. On an enterprise value basis, CARE's 16.3x EV/EBITDA is more attractive than BRBS's 25.1x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $314M | $580M |
| Enterprise ValueMkt cap + debt − cash | $377M | $653M |
| Trailing P/EPrice ÷ TTM EPS | 31.18x | 18.69x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 4.76x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 25.11x | 16.33x |
| Price / SalesMarket cap ÷ Revenue | 2.08x | 2.28x |
| Price / BookPrice ÷ Book value/share | 1.12x | 1.40x |
| Price / FCFMarket cap ÷ FCF | 83.82x | 18.23x |
Profitability & Efficiency
CARE leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
CARE delivers a 7.6% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $3 for BRBS. CARE carries lower financial leverage with a 0.43x debt-to-equity ratio, signaling a more conservative balance sheet compared to BRBS's 0.55x. On the Piotroski fundamental quality scale (0–9), CARE scores 8/9 vs BRBS's 5/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +3.1% | +7.6% |
| ROA (TTM)Return on assets | +0.4% | +0.7% |
| ROICReturn on invested capital | +2.0% | +5.7% |
| ROCEReturn on capital employed | +0.5% | +1.5% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 8 |
| Debt / EquityFinancial leverage | 0.55x | 0.43x |
| Net DebtTotal debt minus cash | $63M | $73M |
| Cash & Equiv.Liquid assets | $116M | $105M |
| Total DebtShort + long-term debt | $179M | $179M |
| Interest CoverageEBIT ÷ Interest expense | 0.23x | 0.39x |
Total Returns (Dividends Reinvested)
CARE leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CARE five years ago would be worth $18,800 today (with dividends reinvested), compared to $3,189 for BRBS. Over the past 12 months, CARE leads with a +68.4% total return vs BRBS's +23.3%. The 3-year compound annual growth rate (CAGR) favors CARE at 24.8% vs BRBS's -18.0% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -6.1% | +34.7% |
| 1-Year ReturnPast 12 months | +23.3% | +68.4% |
| 3-Year ReturnCumulative with dividends | -44.8% | +94.6% |
| 5-Year ReturnCumulative with dividends | -68.1% | +88.0% |
| 10-Year ReturnCumulative with dividends | -13.4% | +111.1% |
| CAGR (3Y)Annualised 3-year return | -18.0% | +24.8% |
Risk & Volatility
Evenly matched — BRBS and CARE each lead in 1 of 2 comparable metrics.
Risk & Volatility
BRBS is the less volatile stock with a 0.54 beta — it tends to amplify market swings less than CARE's 0.56 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CARE currently trades 99.1% from its 52-week high vs BRBS's 71.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.54x | 0.56x |
| 52-Week HighHighest price in past year | $4.79 | $26.41 |
| 52-Week LowLowest price in past year | $3.25 | $15.37 |
| % of 52W HighCurrent price vs 52-week peak | +71.6% | +99.1% |
| RSI (14)Momentum oscillator 0–100 | 32.5 | 75.2 |
| Avg Volume (50D)Average daily shares traded | 378K | 273K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
BRBS is the only dividend payer here at 6.21% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $27.00 |
| # AnalystsCovering analysts | — | 4 |
| Dividend YieldAnnual dividend ÷ price | +6.2% | — |
| Dividend StreakConsecutive years of raises | 0 | 0 |
| Dividend / ShareAnnual DPS | $0.21 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +3.0% | +3.4% |
CARE leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
BRBS vs CARE: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is BRBS or CARE a better buy right now?
For growth investors, Carter Bankshares, Inc.
(CARE) is the stronger pick with 6. 2% revenue growth year-over-year, versus -13. 4% for Blue Ridge Bankshares, Inc. (BRBS). Carter Bankshares, Inc. (CARE) offers the better valuation at 18. 7x trailing P/E (4. 8x forward), making it the more compelling value choice. Analysts rate Carter Bankshares, Inc. (CARE) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BRBS or CARE?
On trailing P/E, Carter Bankshares, Inc.
(CARE) is the cheapest at 18. 7x versus Blue Ridge Bankshares, Inc. at 31. 2x.
03Which is the better long-term investment — BRBS or CARE?
Over the past 5 years, Carter Bankshares, Inc.
(CARE) delivered a total return of +88. 0%, compared to -68. 1% for Blue Ridge Bankshares, Inc. (BRBS). Over 10 years, the gap is even starker: CARE returned +111. 1% versus BRBS's -13. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BRBS or CARE?
By beta (market sensitivity over 5 years), Blue Ridge Bankshares, Inc.
(BRBS) is the lower-risk stock at 0. 54β versus Carter Bankshares, Inc. 's 0. 56β — meaning CARE is approximately 4% more volatile than BRBS relative to the S&P 500. On balance sheet safety, Carter Bankshares, Inc. (CARE) carries a lower debt/equity ratio of 43% versus 55% for Blue Ridge Bankshares, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — BRBS or CARE?
By revenue growth (latest reported year), Carter Bankshares, Inc.
(CARE) is pulling ahead at 6. 2% versus -13. 4% for Blue Ridge Bankshares, Inc. (BRBS). On earnings-per-share growth, the picture is similar: Blue Ridge Bankshares, Inc. grew EPS 135. 5% year-over-year, compared to 32. 1% for Carter Bankshares, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BRBS or CARE?
Carter Bankshares, Inc.
(CARE) is the more profitable company, earning 12. 3% net margin versus 7. 1% for Blue Ridge Bankshares, Inc. — meaning it keeps 12. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CARE leads at 15. 7% versus 9. 1% for BRBS. At the gross margin level — before operating expenses — BRBS leads at 63. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Which pays a better dividend — BRBS or CARE?
In this comparison, BRBS (6.
2% yield) pays a dividend. CARE does not pay a meaningful dividend and should not be held primarily for income.
08Is BRBS or CARE better for a retirement portfolio?
For long-horizon retirement investors, Blue Ridge Bankshares, Inc.
(BRBS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 6. 2% yield). Both have compounded well over 10 years (BRBS: -13. 4%, CARE: +111. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between BRBS and CARE?
Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BRBS is a small-cap income-oriented stock; CARE is a small-cap quality compounder stock. BRBS pays a dividend while CARE does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.